|
Unit:
|
Bureau of Industry and Information Technology, Haicang District; Xiamen Haicang Biotechnology Development Co., Ltd.; Bureau of Industry and Information Technology, Xiang’an District
|
|
|
Project Area:
|
xiamen Xiamen Biomedical Port; Xiang’an Digital Economy Industrial Park
|
|
|
Industry:
|
Biological and New Pharmaceutical Industry
|
|
|
Type of Project:
|
New Project
|
|
|
Cooperation Mode:
|
Collaborate
|
|
|
Nature of Project:
|
Encourage
|
|
|
Working Progress in Prior Period:
|
none
|
|
|
Total Investment:
|
discussed in detai
|
|
|
Expected to Attract Investment:
|
discussed in detai
|
|
|
Benefit Analysis:
|
none
|
|
|
Reason and Condition:
|
none
|
|
|
Content and Scale:
|
1. Xiamen Biomedical Port: It intends to introduce enterprises of new type vaccines, recombinant protein drugs, biomacromolecule drugs, innovative small molecule drugs, siRNA drugs, targeted drugs, and modified new drugs. It also introduces platforms for the design, screening, and validation of innovative chemical drugs, platforms for new types of drug carriers and sustained-controlled-release technologies and modern high-end biomedical projects.2. Xiang’an Digital Economy Industrial Park: It plans to introduce in vitro diagnostic reagents and core raw materials such as immunodiagnostics, molecular diagnosis, POCT, and a new generation of fully automated diagnostic equipment. All kinds of artificial organs, cardiovascular, nerve, and other high-end implantable interventional products, high-end medical imaging equipment, tumor treatment equipment, respiratory equipment, and consumables. It will also develop health management equipment and high-performance medical devices such as chronic disease monitoring and management, wearable remote diagnosis and treatment, and remote health management.
|
|
|
Others:
|
none
|
|
In 2025, Fujian Province had 341 above-designated-size pharmaceutical enterprises, achieving an operating revenue of RMB 50.28 billion. The province's pharmaceutical industry has cultivated a relatively comprehensive industrial system covering categories such as chemical APIs (active pharmaceutical ingredients), chemical drug preparations, biopharmaceuticals, traditional Chinese medicine (TCM) prepared prescriptions, TCM decoction pieces, and medical devices. During the "14th Five-Year Plan" period, 4 Category-1 innovative drugs and 4 Category-2 innovative drugs were approved, accelerating industrial innovation. Maxim Biotech and Double Medical were promoted as leaders in the industrial chain. 6 projects from 3 enterprises, including Double Medical, were shortlisted for the Ministry of Industry and Information Technology's List of “Open Bidding for Selecting the Best Candidates for Innovation Tasks in Biomedical Materials.” 11 provincial-level industrial leading enterprises in biomedicine, such as Zhangzhou Pien Tze Huang Pharmaceuticals, and 17 enterprises under cultivation for leading status were fostered. 3 enterprises, including AmoyDx, were recognized as national single-item champions (in specific products); 25 enterprises, including Fukang Pharmaceuticals, were recognized as provincial single-item champions (in specific products). 19 pharmaceutical enterprises, including Southern Pharmaceuticals and Fukang Pharmaceuticals, were recognized as National "Little Giants" Enterprises Using Specialized and Advanced Technologies to Create Innovative and Unique Products. 15 enterprises, including Double Medical, Cosunter Pharmaceutical, and Haixi Pharmaceuticals, are listed companies.